These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24240066)

  • 1. Relationship between the effect of eldecalcitol and serum 25(OH)D level.
    Takano T; Kondo S; Saito H; Matsumoto T;
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():124-7. PubMed ID: 24240066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eldecalcitol increases bone mineral density in Chinese osteoporotic patients without vitamin D or calcium supplementation.
    Jiang Y; Tang H; Ma X; Cheng Q; Lin H; Jin X; Zhang Z; Yu W; He S; Kobayashi T; Uehara S; Matsumoto T; Xia W
    J Bone Miner Metab; 2019 Nov; 37(6):1036-1047. PubMed ID: 31087185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study.
    Matsumoto T; Ito M; Hayashi Y; Hirota T; Tanigawara Y; Sone T; Fukunaga M; Shiraki M; Nakamura T
    Bone; 2011 Oct; 49(4):605-12. PubMed ID: 21784190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA).
    Matsumoto T; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Nakano T; Ito M; Tomomitsu T; Hirakawa A; Soen S
    J Bone Miner Metab; 2020 Jul; 38(4):522-532. PubMed ID: 32140784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eldecalcitol: newly developed active vitamin D(3) analog for the treatment of osteoporosis.
    Hagino H
    Expert Opin Pharmacother; 2013 Apr; 14(6):817-25. PubMed ID: 23477453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eldecalcitol for the treatment of osteoporosis.
    Matsumoto T; Endo I
    Drugs Today (Barc); 2012 Mar; 48(3):189-96. PubMed ID: 22462038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
    Iba K; Sonoda T; Takada J; Dohke T; Yamashita T
    J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eldecalcitol: a review of its use in the treatment of osteoporosis.
    Sanford M; McCormack PL
    Drugs; 2011 Sep; 71(13):1755-70. PubMed ID: 21902297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current Topics on Vitamin D. Treatment of osteoporosis with eldecalcitol: Its therapeutic efficacy and adverse effect on renal function].
    Takeuchi Y
    Clin Calcium; 2015 Mar; 25(3):425-32. PubMed ID: 25716816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eldecalcitol for the treatment of osteoporosis.
    Noguchi Y; Kawate H; Nomura M; Takayanagi R
    Clin Interv Aging; 2013; 8():1313-21. PubMed ID: 24101867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eldecalcitol is more effective for the prevention of osteoporotic fractures than alfacalcidol.
    Nakamura T; Takano T; Fukunaga M; Shiraki M; Matsumoto T
    J Bone Miner Metab; 2013 Jul; 31(4):417-22. PubMed ID: 23575909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects.
    Matsumoto T; Kubodera N
    J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):584-6. PubMed ID: 17298881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Frontiers in vitamin D; Basic research and clinical application. The effects of eldecalcitol on bone mineral density and fracture prevention--Post hoc analysis].
    Hagino H
    Clin Calcium; 2011 Nov; 21(11):111-8. PubMed ID: 22040827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials.
    Mawatari T; Muraoka R; Iwamoto Y
    Osteoporos Int; 2017 Apr; 28(4):1279-1286. PubMed ID: 27900428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
    Ringe JD; Farahmand P; Schacht E; Rozehnal A
    Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
    Ringe JD; Faber H; Fahramand P; Schacht E
    J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis.
    Hagino H; Takano T; Fukunaga M; Shiraki M; Nakamura T; Matsumoto T
    J Bone Miner Metab; 2013 Mar; 31(2):183-9. PubMed ID: 23129180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
    Reginster JY; Lecart MP; Richy F
    J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Frontiers in vitamin D; basic research and clinical application. Eldecalcitol: the effect on bones and calcium metabolism].
    Endo I; Matsumoto T
    Clin Calcium; 2011 Nov; 21(11):103-10. PubMed ID: 22040826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eldecalcitol normalizes bone turnover markers regardless of their pre-treatment levels.
    Shiraki M; Saito H; Matsumoto T
    Curr Med Res Opin; 2012 Sep; 28(9):1547-52. PubMed ID: 22794117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.